Comparative Efficacy of Interventions on Nonalcoholic Fatty Liver Disease (NAFLD): A PRISMA-compliant Systematic Review and Network Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2016 Aug 12

PMID 27512874

Citations 30

Authors

Ratree Sawangjit

Bunchai Chongmelaxme

Pochamana Phisalprapa

Surasak Saokaew

Ammarin Thakkinstian

Kris V Kowdley

Nathorn Chaiyakunapruk

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) has significantly increased over the last decades. Despite existence of several interventions, there remains unclear which interventions work the best.

Methods: A systematic review and network meta-analysis of randomized trials comparing efficacy of all treatment options in NAFLD were performed to determine comparative efficacy and safety of interventions in the management of NAFLD. Several electronic databases were searched up to Nov 15, 2015. Outcomes include liver histological outcomes (i.e., fibrosis), all-cause mortality, cirrhosis, and safety. A network meta-analysis was applied to estimate pooled risk ratios (RR). Quality of evidence was assessed using GRADE criteria.

Results: A total of 44 studies (n = 3802) were eligible. When compared with placebo, obeticholic acid (OCA) was the only intervention that significantly improved fibrosis with RR (95% CI) of 1.91 (1.15, 3.16), while pentoxyfylline (PTX) demonstrated improved fibrosis without statistical significance with RR (95% CI) of 2.27 (0.81, 6.36). Only thiazolidinedione (TZD) and vitamin E use resulted in significant increase in resolution of NASH, while OCA, TZD, and vitamin E significantly improved other outcomes including NAS, steatosis, ballooning, and inflammation outcomes. Quality of evidence varied from very low (i.e., metformin, PTX on mean change of ballooning grade) to high (OCA, TZD, vitamin E on improving histological outcomes). Limitations of this study were lack of relevant long-term outcomes (e.g., cirrhosis, death, safety), possible small study effect, and few head-to-head studies.

Conclusions: Our study suggests potential efficacy of OCA, TZD, and vitamin E in improving histologic endpoints in NAFLD. These findings are however based on a small number of studies. Additional studies are awaited to strengthen this network meta-analysis.

Citing Articles

Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting.

Linero P, Castilla-Guerra L Eur Cardiol. 2024; 19:e02.

PMID: 38807854 PMC: 11131151. DOI: 10.15420/ecr.2023.19.

Metformin and the Liver: Unlocking the Full Therapeutic Potential.

Perazza F, Leoni L, Colosimo S, Musio A, Bocedi G, DAvino M Metabolites. 2024; 14(4).

PMID: 38668314 PMC: 11052067. DOI: 10.3390/metabo14040186.

Pump-Less, Recirculating Organ-on-Chip (rOoC) Platform to Model the Metabolic Crosstalk between Islets and Liver.

Aizenshtadt A, Wang C, Abadpour S, Menezes P, Wilhelmsen I, Dalmao-Fernandez A Adv Healthc Mater. 2024; 13(13):e2303785.

PMID: 38221504 PMC: 11468483. DOI: 10.1002/adhm.202303785.

The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.

Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E Eur J Clin Pharmacol. 2023; 80(1):127-150.

PMID: 37938366 PMC: 10781828. DOI: 10.1007/s00228-023-03586-1.

Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.

Cheng P, Chen W, Hou C, Lin C, Chang M, Wang C Clin Mol Hepatol. 2023; 30(1):16-36.

PMID: 37793641 PMC: 10776290. DOI: 10.3350/cmh.2023.0315.

References

Shields W, Thompson K, Grice G, Harrison S, Coyle W . The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol. 2010; 2(3):157-63. PMC: 3002518. DOI: 10.1177/1756283X09105462. View

Dechartres A, Altman D, Trinquart L, Boutron I, Ravaud P . Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA. 2014; 312(6):623-30. DOI: 10.1001/jama.2014.8166. View

Li Y, Yang L, Sha K, Liu T, Zhang L, Liu X . Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol. 2015; 21(22):7008-13. PMC: 4462743. DOI: 10.3748/wjg.v21.i22.7008. View

Musso G, Cassader M, Rosina F, Gambino R . Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012; 55(4):885-904. DOI: 10.1007/s00125-011-2446-4. View

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

Berry D, Wathen J, Newell M . Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials. 2009; 6(1):28-41. DOI: 10.1177/1740774508101279. View

Cipriani A, Higgins J, Geddes J, Salanti G . Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013; 159(2):130-7. DOI: 10.7326/0003-4819-159-2-201307160-00008. View

Argo C, Patrie J, Lackner C, Henry T, de Lange E, Weltman A . Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2014; 62(1):190-7. PMC: 4272639. DOI: 10.1016/j.jhep.2014.08.036. View

Van Wagner L, Koppe S, Brunt E, Gottstein J, Gardikiotes K, Green R . Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011; 10(3):277-86. View

10.

Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L . Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135(1):100-10. DOI: 10.1053/j.gastro.2008.03.078. View

11.

Georgescu E, Ionescu R, Niculescu M, Mogoanta L, Vancica L . Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009; 15(8):942-54. PMC: 2653406. DOI: 10.3748/wjg.15.942. View

12.

Abdelmalek M, Sanderson S, Angulo P, Soldevila-Pico C, Liu C, Peter J . Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology. 2009; 50(6):1818-26. DOI: 10.1002/hep.23239. View

13.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

14.

Sturm N, Bronowicki J, Maynard-Muet M, Tran A, Heluwaert F, Plages A . Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial. Gastroenterol Clin Biol. 2009; 33(10-11):984-6. DOI: 10.1016/j.gcb.2009.05.010. View

15.

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

16.

Dietrich M, Jacques P, Pencina M, Lanier K, Keyes M, Kaur G . Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?. Atherosclerosis. 2009; 205(2):549-53. PMC: 2717181. DOI: 10.1016/j.atherosclerosis.2008.12.019. View

17.

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View

18.

Shenoy K, Balakumaran L, Mathew P, Prasad M, Prabhakar B, Sood A . Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial. J Clin Exp Hepatol. 2015; 4(2):94-100. PMC: 4116708. DOI: 10.1016/j.jceh.2014.03.041. View

19.

Sanyal A, Friedman S, McCullough A, Dimick-Santos L . Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015; 61(4):1392-405. PMC: 4900161. DOI: 10.1002/hep.27678. View

20.

Singh S, Khera R, Allen A, Murad M, Loomba R . Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015; 62(5):1417-32. DOI: 10.1002/hep.27999. View